Northside Capital Management LLC Acquires 6,924 Shares of Becton, Dickinson and Company $BDX

Northside Capital Management LLC lifted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 15.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,012 shares of the medical instruments supplier’s stock after purchasing an additional 6,924 shares during the period. Northside Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $9,922,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Brighton Jones LLC boosted its holdings in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 877 shares in the last quarter. Steward Partners Investment Advisory LLC boosted its stake in Becton, Dickinson and Company by 4.8% during the first quarter. Steward Partners Investment Advisory LLC now owns 29,485 shares of the medical instruments supplier’s stock worth $6,754,000 after acquiring an additional 1,343 shares in the last quarter. Northern Trust Corp increased its stake in Becton, Dickinson and Company by 3.2% in the first quarter. Northern Trust Corp now owns 2,811,239 shares of the medical instruments supplier’s stock valued at $643,942,000 after purchasing an additional 86,885 shares in the last quarter. Aptus Capital Advisors LLC raised its holdings in shares of Becton, Dickinson and Company by 6.8% during the first quarter. Aptus Capital Advisors LLC now owns 14,651 shares of the medical instruments supplier’s stock valued at $3,356,000 after purchasing an additional 927 shares during the period. Finally, HC Advisors LLC bought a new position in shares of Becton, Dickinson and Company during the 1st quarter worth about $229,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 1.8%

BDX opened at $196.42 on Wednesday. Becton, Dickinson and Company has a fifty-two week low of $162.29 and a fifty-two week high of $251.99. The firm has a market capitalization of $56.06 billion, a P/E ratio of 33.69, a PEG ratio of 1.85 and a beta of 0.25. The company’s 50-day moving average is $189.15 and its 200 day moving average is $185.02. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.11 and a quick ratio of 0.64.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The firm had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. Research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 31st. Investors of record on Monday, December 8th will be given a dividend of $1.05 per share. The ex-dividend date is Monday, December 8th. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 annualized dividend and a yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 72.04%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of Becton, Dickinson and Company stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $176.58, for a total value of $38,317.86. Following the sale, the director owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. The trade was a 0.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 407 shares of company stock worth $73,922 in the last three months. Company insiders own 0.36% of the company’s stock.

Wall Street Analyst Weigh In

BDX has been the subject of a number of research analyst reports. Argus boosted their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Royal Bank Of Canada lowered their target price on Becton, Dickinson and Company from $211.00 to $202.00 and set a “sector perform” rating on the stock in a research report on Friday, November 7th. Stifel Nicolaus reduced their price target on shares of Becton, Dickinson and Company from $224.00 to $210.00 in a research report on Friday, November 7th. Finally, Morgan Stanley boosted their price target on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Four analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, Becton, Dickinson and Company has a consensus rating of “Hold” and a consensus target price of $204.91.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.